IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Position Increased by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,617 shares of the company’s stock after buying an additional 52 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in IDEXX Laboratories were worth $1,495,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Proficio Capital Partners LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $62,391,000. Assetmark Inc. increased its position in shares of IDEXX Laboratories by 83.4% in the fourth quarter. Assetmark Inc. now owns 33,804 shares of the company’s stock worth $13,976,000 after acquiring an additional 15,377 shares in the last quarter. Crew Capital Management Ltd. increased its position in shares of IDEXX Laboratories by 24.0% in the fourth quarter. Crew Capital Management Ltd. now owns 2,569 shares of the company’s stock worth $1,062,000 after acquiring an additional 498 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of IDEXX Laboratories by 21.4% in the fourth quarter. Victory Capital Management Inc. now owns 173,131 shares of the company’s stock worth $71,579,000 after acquiring an additional 30,503 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its position in shares of IDEXX Laboratories by 39.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 918 shares of the company’s stock worth $379,000 after acquiring an additional 262 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $430.12 on Friday. The company has a market capitalization of $34.98 billion, a price-to-earnings ratio of 40.31, a P/E/G ratio of 3.41 and a beta of 1.39. The firm’s 50 day simple moving average is $437.37 and its 200 day simple moving average is $449.72. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $574.94.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IDXX shares. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.